A tidal wave of questions floats the need for more upstream automation.

The Making of mRNA

The milestone approval of a gene-edited therapeutic paves the way for gene-editing technologies.

Milestone Approval to Steady Stream, Gene Editing Revs Up

Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.

The Pros and Cons of Adherent Versus Suspension Cell Culture

Topic

Webcasts

Webinar Date/Time: Thu, Oct 31, 2024 11:00 AM EDT


Accelerating High-Titer Expression for Complex Next-Gen Biologics

Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT


Oral Lipid-Based Formulations: Unlocking Value in Early-Stage Pharmaceutical Development

Roxana McCloskey is senior global marketing manager, Protein Therapeutics, at SCIEX.

Zoe Zhang is manager, Biopharma Applications, at SCIEX.

Articles

Stable cell line development can benefit from applying integrated analytical technologies.

Ensuring Cell Line Stability for Protein Therapeutics

Automation technologies used in the development and manufacture of biopharmaceuticals continue to evolve, providing the potential for reduced costs and time.

Streamlining Bioprocesses with Automation

Feliza Mirasol is the science editor for 

Optimizing AAV vector manufacturing will be necessary to meet anticipated future market demand.

Optimizing Expression Systems for AAV Vectors

Simon Keen, vice president Cell Line Development, Abzena

Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.

Optimizing Cell Line Development for Next Generation Biologics

AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.

AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Using a multi-pronged strategy to find optimum, tailored formulations is best.

Addressing the Complexities of Media Formulation Development

Michael Mcilhatton, PhD, is a Senior Scientist, process development lab, at Andelyn Biosciences.

is a Senior Scientist, process development lab, at Andelyn Biosciences.

Sarah Bergman is a scientist, process development lab, at Andelyn Biosciences.

Brittany Hurley is a scientist, process development lab, at Andelyn Biosciences.

scientist, process development, at Andelyn Biosciences.

Andrew Moreo oversees process development, preclinical plasmid production, and viral vector production at Andelyn Biosciences.

Associate Director of Process Development at Andelyn Biosciences.

This commentary summarizes the derivation of clonal HEK293 suspension cell lines, selection of clones for rAAV production, and design of experiments-based optimization strategies for characterization of one clonal isolate for high yield rAAV manufacture. Data shown provides proof of concept for the success of this strategy, its applicability for manufacturing different rAAV serotypes and lays the foundation of further clonal cell line characterization for scale up of production.

Strategy for Derivation and Optimization of a Clonal HEK293 Suspension Cell Line for High Yield AAV Production

Chris Spivey is the editorial director of 

Videos

Global product manager at Cytiva, Eric Corti, discusses the challenges with designing a new single-use mixing system that ensures leak-free fluid handling operations at INTERPHEX 2024.

Upstream Processing

The Making of mRNA

Milestone Approval to Steady Stream, Gene Editing Revs Up

The Pros and Cons of Adherent Versus Suspension Cell Culture